{"id":"affitope-pd01a","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"The drug works by stimulating the production of antibodies that specifically target and neutralize misfolded alpha-synuclein, potentially slowing the progression of the disease.","oneSentence":"AFFITOPE® PD01A is designed to induce an immune response against alpha-synuclein, a protein implicated in Parkinson's disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T05:51:10.008Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT02270489","phase":"PHASE1","title":"Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA","status":"COMPLETED","sponsor":"Affiris AG","startDate":"2014-12-11","conditions":"Multiple System Atrophy, Neurodegenerative Diseases","enrollment":30},{"nctId":"NCT02618941","phase":"PHASE1","title":"Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)","status":"COMPLETED","sponsor":"Affiris AG","startDate":"2016-02-02","conditions":"Parkinson's Disease","enrollment":26},{"nctId":"NCT02758730","phase":"PHASE1","title":"Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients","status":"WITHDRAWN","sponsor":"Affiris AG","startDate":"","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT02216188","phase":"PHASE1","title":"Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity","status":"COMPLETED","sponsor":"Affiris AG","startDate":"2014-08","conditions":"Parkinson's Disease","enrollment":28},{"nctId":"NCT01885494","phase":"","title":"AFF008E: Observational Phase 1b Follow-up Extension Study for Patients With Parkinson's Disease After Immunization With AFFITOPE® PD01A","status":"COMPLETED","sponsor":"Affiris AG","startDate":"2013-06","conditions":"Parkinson's Disease","enrollment":30},{"nctId":"NCT01568099","phase":"PHASE1","title":"Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease","status":"COMPLETED","sponsor":"Affiris AG","startDate":"2012-02","conditions":"Parkinson's Disease","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AFFITOPE® PD01A","genericName":"AFFITOPE® PD01A","companyName":"Affiris AG","companyId":"affiris-ag","modality":"Biologic","firstApprovalDate":"","aiSummary":"AFFITOPE® PD01A is designed to induce an immune response against alpha-synuclein, a protein implicated in Parkinson's disease. Used for Parkinson's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}